Clinical Trials Directory

Trials / Completed

CompletedNCT00594451

Gene-Environment Interactions in Rheumatoid Arthritis Autoimmunity Disease Severity

Gene-Environment Interactions in RA Autoimmunity Disease Severity

Status
Completed
Phase
Study type
Observational
Enrollment
800 (actual)
Sponsor
University of Nebraska · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The objective of the proposed study is to assess the role of smoking and complex gene-smoking interactions in two understudied Rheumatoid Arthritis (RA)groups.

Detailed description

Rheumatoid Arthritis (RA) is a systemic inflammatory disease affecting over 2 million people in the U.S. alone, a condition characterized by progressive joint destruction, significant work-related disability and accelerated mortality. While the precise cause of RA is unknown, it is clear that the disease does not result from a single heritable factor or single environmental exposure. Of the many environmental exposures that have been studied, cigarette smoking is the factor most consistently shown to be associated with RA onset. In addition to its role in disease susceptibility, recent studies have found that smoking, along with genetic factors, contribute to RA-related autoimmunity and disease severity. Moreover, studies to date looking at disease severity in RA have exclusively involved women of Caucasian/European ancestry. This is an important distinction since although RA is more common in women, smoking appears to be most closely linked to RA risk in men. Additionally, the burden of other smoking-related illnesses appears to be greatest among non-Caucasian populations. For this reason and because smoking rates and prevalence of risk-alleles differ in ethnic/racial minorities (i.e. SE and GSTM1-null polymorphism), further studies are needed to define the association of smoking and possible gene-smoking interactions and their role in autoimmunity and disease severity in these understudied populations.

Conditions

Timeline

Start date
2006-10-19
Primary completion
2010-04-01
Completion
2013-01-01
First posted
2008-01-15
Last updated
2023-09-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00594451. Inclusion in this directory is not an endorsement.